Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Cytometry
|
March 27, 1998
A novel bioassay for P-glycoprotein functionality using cytochalasin D
L Elbling, W Berger, R M Weiss, et al.
International Journal of Cancer
|
December 18, 2001
Overexpression of the human major vault protein in astrocytic brain tumor cells
W Berger, S Spiegl-Kreinecker, J Buchroithner, et al.
International Journal of Cancer
|
December 1, 1994
Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines
W Berger, L Elbling, M Minai-Pour, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
August 4, 2005
Methods for the detection of antioxidants which prevent age related diseases: a critical review with particular emphasis on human intervention studies
C Hoelzl, J Bichler, F Ferk, et al.
Journal of Cancer Research and Clinical Oncology
|
April 28, 2005
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications
Walter Berger, Ulrike Setinek, Peter Hollaus, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
April 8, 2006
Anticancer effects of zoledronic acid against human osteosarcoma cells
B Kubista, K Trieb, F Sevelda, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
Current Cancer Drug Targets
|
June 11, 2009
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)
P Heffeter, A Popovic-Bijelic, P Saiko, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Cytometry
|
March 27, 1998
A novel bioassay for P-glycoprotein functionality using cytochalasin D
L Elbling, W Berger, R M Weiss, et al.
International Journal of Cancer
|
December 18, 2001
Overexpression of the human major vault protein in astrocytic brain tumor cells
W Berger, S Spiegl-Kreinecker, J Buchroithner, et al.
International Journal of Cancer
|
December 1, 1994
Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines
W Berger, L Elbling, M Minai-Pour, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|
August 4, 2005
Methods for the detection of antioxidants which prevent age related diseases: a critical review with particular emphasis on human intervention studies
C Hoelzl, J Bichler, F Ferk, et al.
Journal of Cancer Research and Clinical Oncology
|
April 28, 2005
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications
Walter Berger, Ulrike Setinek, Peter Hollaus, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|
April 8, 2006
Anticancer effects of zoledronic acid against human osteosarcoma cells
B Kubista, K Trieb, F Sevelda, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
Current Cancer Drug Targets
|
June 11, 2009
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)
P Heffeter, A Popovic-Bijelic, P Saiko, et al.
Page
of 3